TY - JOUR
T1 - Cisplatin, etoposide, and vincristine combination chemotherapy in the treatment of non-small cell lung cancer.
AU - Watanabe, A.
AU - Ichiyama, S.
AU - Shimokata, K.
AU - Nagura, E.
AU - Saito, H.
AU - Saka, H.
AU - Nomura, F.
AU - Sakai, S.
AU - Saito, H.
PY - 1993/3
Y1 - 1993/3
N2 - Thirty patients with previously untreated, inoperable non-small cell lung cancer (NSCLC) were treated with cisplatin, etoposide and vincristine. Among twenty-nine evaluable patients, eight patients achieved partial response and the overall response rate was 28%. No patient achieved a complete response. The median survival time was 51 weeks. Myelosuppression was the dose-limiting toxicity. Four patients had a leukocyte nadir of less than 1000/mm3, and one died from severe myelosuppression and sepsis. The other toxicities were nausea/vomiting, peripheral neuropathy, and alopecia. We conclude that cisplatin, etoposide, and vincristine combination chemotherapy offers moderate activity for inoperable non-small cell lung cancer.
AB - Thirty patients with previously untreated, inoperable non-small cell lung cancer (NSCLC) were treated with cisplatin, etoposide and vincristine. Among twenty-nine evaluable patients, eight patients achieved partial response and the overall response rate was 28%. No patient achieved a complete response. The median survival time was 51 weeks. Myelosuppression was the dose-limiting toxicity. Four patients had a leukocyte nadir of less than 1000/mm3, and one died from severe myelosuppression and sepsis. The other toxicities were nausea/vomiting, peripheral neuropathy, and alopecia. We conclude that cisplatin, etoposide, and vincristine combination chemotherapy offers moderate activity for inoperable non-small cell lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=0027571590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027571590&partnerID=8YFLogxK
M3 - Article
C2 - 8247105
AN - SCOPUS:0027571590
SN - 0027-7622
VL - 55
SP - 41
EP - 46
JO - Nagoya journal of medical science
JF - Nagoya journal of medical science
IS - 1-4
ER -
